The preference for DR5 targeting is due to accumulating evidence that DR5 expression in cancers is more universal and at higher levels than that of DR4 and that DR5 is overexpressed in the majority of cancerous tissues compared to normal tissues [30–41]. The gene discussed is TNFRSF10A; the disease is cancer.